Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00KHM
|
||||
| Former ID |
DAP000316
|
||||
| Drug Name |
Pimozide
|
||||
| Synonyms |
Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Approved | [1], [2] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
Janssen Pharmaceutica
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H29F2N3O
|
||||
| InChI |
InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
|
||||
| InChIKey |
YVUQSNJEYSNKRX-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 2062-78-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9769, 563187, 855710, 6706026, 7847626, 7980325, 8137196, 8149730, 8162258, 10321421, 11111615, 11112507, 11113804, 11335561, 11360800, 11363339, 11365901, 11368463, 11372540, 11373859, 11376625, 11447004, 11461772, 11466336, 11467456, 11484947, 11486231, 11488842, 11491266, 11492235, 11494259, 12013418, 14882544, 17405504, 24277923, 26612186, 26680826, 26747138, 26747139, 26751488, 26751978, 26751979, 29284219, 46507096, 47275121, 47275122, 47423792, 47572947, 47720184, 47720185
|
||||
| ChEBI ID |
ChEBI:8212
|
||||
| SuperDrug ATC ID |
N05AG02
|
||||
| SuperDrug CAS ID |
cas=002062784
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [3], [4] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017473. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 90). | ||||
| REF 3 | Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. | ||||
| REF 4 | The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.